Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Up on Earnings Beat

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY)’s stock price gapped up before the market opened on Monday following a better than expected earnings announcement. The stock had previously closed at $9.04, but opened at $9.70. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $9.70, with a volume of 8,568 shares.

The company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.18. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 13.56% and a net margin of 41.08%.

Analysts Set New Price Targets

SGIOY has been the topic of several recent analyst reports. The Goldman Sachs Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a report on Monday, June 15th. Zacks Research raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a research report on Monday, May 25th. Finally, Jefferies Financial Group raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 14th. Two analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Shionogi & Co., Ltd. Unsponsored ADR has a consensus rating of “Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Stock Up 7.3%

The firm has a fifty day simple moving average of $8.82 and a 200-day simple moving average of $9.88. The company has a market capitalization of $16.51 billion, a PE ratio of 12.13, a P/E/G ratio of 3.55 and a beta of 0.09. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.46 and a current ratio of 1.58.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.